XyloCor Therapeutics

heart art heart failure genes
Biotech

XyloCor gene therapy hits goals, paving way for pivotal trial

XyloCor Therapeutics’ lead gene therapy candidate has met both safety and efficacy goals among patients with refractory angina in a phase 1/2 trial.
Gabrielle Masson Jan 26, 2023 11:56am
neon red heart outline on black background

XyloCor bags $23M to expand heart disease gene therapy R&D

Mar 22, 2021 9:20am